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Abstract
Background: Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of
type 2 diabetes mellitus (T2DM).
Methods:
14C-alpha-methylglucoside uptake in Chinese hamster ovary-K cells expressing human, rat, or mouse SGLT2 or
SGLT1;
3H-2-deoxy-D-glucose uptake in L6 myoblasts; and 2-electrode voltage clamp recording of oocytes expressing
human SGLT3 were analyzed. Graded glucose infusions were performed to determine rate of urinary glucose excretion
(UGE) at different blood glucose (BG) concentrations and the renal threshold for glucose excretion (RTG) in vehicle or
canagliflozin-treated Zucker diabetic fatty (ZDF) rats. This study aimed to characterize the pharmacodynamic effects of
canagliflozin in vitro and in preclinical models of T2DM and obesity.
Results: Treatment with canagliflozin 1 mg/kg lowered RTG from 415612 mg/dl to 94610 mg/dl in ZDF rats while
maintaining a threshold relationship between BG and UGE with virtually no UGE observed when BG was below RTG.
Canagliflozin dose-dependently decreased BG concentrations in db/db mice treated acutely. In ZDF rats treated for 4 weeks,
canagliflozin decreased glycated hemoglobin (HbA1c) and improved measures of insulin secretion. In obese animal models,
canagliflozin increased UGE and decreased BG, body weight gain, epididymal fat, liver weight, and the respiratory exchange
ratio.
Conclusions: Canagliflozin lowered RTG and increased UGE, improved glycemic control and beta-cell function in rodent
models of T2DM, and reduced body weight gain in rodent models of obesity.
Citation: Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, et al. (2012) Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in
Normal and Diabetic Animal Models. PLoS ONE 7(2): e30555. doi:10.1371/journal.pone.0030555
Editor: Gian Paolo Fadini, University of Padova Medical School, Italy
Received August 30, 2011; Accepted December 19, 2011; Published February 15, 2012
Copyright:  2012 Liang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Johnson & Johnson Pharmaceutical Research & Development, LLC. sponsored this study. Editorial assistance was provided by Phase Five
Communications, Inc., and supported by Janssen Global Services, LLC. The authors are all employees of Johnson & Johnson Pharmaceutical Research &
Development, LLC. or Mitsubishi Tanabe Pharma Corporation, and as such, designed the studies, participated in data collection and analysis, made the decision to
publish, and prepared the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: Drs. Liang, Martin, Du, Conway, Polidori, and Demarest are
employees of Johnson & Johnson Pharmaceutical Research & Development, LLC. Drs. Arakawa, Ueta, Matsushita, and Kuriyama are employees of Mitsubishi
Tanabe Pharma Corporation, Japan. Canagliflozin (JNJ-28431754/TA-7284) is being developed by Johnson & Johnson Pharmaceutical Research & Development,
LLC. in collaboration with Mitsubishi Tanabe Pharma Corporation. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and
materials.
* E-mail: yliang@its.jnj.com
Introduction
Due in part to the increasing prevalence of obesity and the
aging of the global population, type 2 diabetes (T2DM) is
becoming an increasingly prevalent disorder [1]. While lifestyle
interventions are effective means to improve glycemic control, as
beta-cell loss ensues and illness progresses, patients require
increasingly complex therapies involving combinations of anti-
hyperglycemic agents, including insulin, in order to attain optimal
glycemic control. Currently approved antihyperglycemic agents
act by increasing insulin secretion, enhancing insulin sensitivity, or
reducing glucose absorption. Despite the availability of a
pharmacologic armamentarium containing a number of effica-
cious antihyperglycemic agents, fewer than 50% of patients
achieve glycemic treatment goals set forth by expert societies [2].
In a normoglycemic person, approximately 180 grams of blood
glucose (BG) is filtered by the glomerulus and is resorbed in the
proximal tubule such that urinary glucose excretion (UGE) is
negligible [3,4]. As plasma glucose concentrations increase above
normal, UGE remains negligible until the filtered glucose load
begins to saturate the capacity of the renal glucose transporters.
The plasma glucose concentration at which this occurs is called the
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renal glucose resorption is mediated by sodium glucose co-
transporter 2 (SGLT2), a high-capacity, low-affinity glucose
transporter localized in the luminal membrane of early proximal
renal tubular cells [3,4]. Once transported by SGLT2 into the
tubular cell, glucose is transported down its concentration
gradient and into the renal interstitium by the facilitative glucose
transporter 2 (GLUT2) [3,4]. The filtered glucose not resorbed
by SGLT2 is subsequently resorbed in more distal portions of the
proximal tubule by SGLT1, a high-affinity, low-capacity glucose
transporter and is transported from the proximal tubular cell into
the renal interstitium by the facilitative GLUT1 [3,4]. Although
SGLT2 and SGLT1 are believed to transport the vast majority of
glucose from the tubular lumen, other less well-characterized
glucose transporters may also be involved in renal glucose
resorption [5].
SGLT2 is expressed almost exclusively in the proximal tubule
of the kidney [3,4]. Mutations in the SLC5A2 gene encoding
SGLT2 are found in persons with familial renal glucosuria (FRG)
[6]; FRG is considered a benign condition, with affected
individuals exhibiting glucosuria in the absence of hyperglycemia
without alteration in other proximal tubular functions [6].
Recently, an SGLT2-null mouse was generated, its phenotype
similar to that of persons with FRG [7]. SGLT1 is expressed
predominantly in the intestine and to a lesser extent in the
proximal tubule of the kidney [3,4,7]. Mutations in the SLC5A1
gene encoding SGLT1 are found in persons with glucose-
galactose malabsorption [3,7]. Persons with this disorder have
severe, life-threatening diarrhea due to hexose malabsorption
[3,7]. Attesting to the minor role for SGLT1 in renal glucose
resorption under normoglycemic conditions, these persons exhibit
only minimal glucosuria [8]. If treated with a glucose-galactose-
deficient diet, the growth and development of these individuals
can be normal [3].
Phlorizin, a nonselective inhibitor of SGLT1 and SGLT2,
reduces BG in preclinical models of T2DM [9] and, due to its
insulin-independent mechanism of action, also lowers BG in
models of type 1 diabetes [9,10]. Due to its nonselective nature
and its poor pharmaceutical properties, phlorizin is unsuitable for
clinical development [11]. Recently, a number of selective,
metabolically stable SGLT2 inhibitors have been discovered and
are in clinical development to treat T2DM [12–14].
Canagliflozin, one of these SGLT2 inhibitors, is currently in
clinical development. In this report, we describe the selectivity and
potency of canagliflozin and characterize its effects on UGE, RTG,
glycemic control, glucose-stimulated insulin secretion, energy
expenditure, and body weight in preclinical models of T2DM
and insulin resistance.
Materials and Methods
Ethics Statement
All animal work was conducted according to relevant national
and international guidelines. Full details of the study was approved
by Johnson & Johnson PRD IASCUC committee (SH-MET-
3011).
Reagents and Chemicals
Canagliflozin was synthesized by Mitsubishi Tanabe Pharma
Corporation, Medicinal Chemistry Laboratory (Toda, Saitama,
Japan) [15]. Primers, vectors, and tissue culture media were
purchased from Invitrogen (Carlsbad, California, USA). All other
chemicals, unless otherwise specified, were purchased from Sigma
(St. Louis, Missouri, USA).
Cell-based Assays
Sodium-dependent Glucose Uptake in Chinese Hamster Ovary
(CHO) Cells Expressing SGLT1 and SGLT2 Co-transporters
Parental CHO-K (CHOK) cells (commonly used mammalian cells
for gene overexpression studies) expressing human or mouse
SGLT1 and SGLT2 were utilized in this study. Cells were seeded
into 96-well plates. Cells were then washed one time with 0.15 ml
assay buffer (137 mM NaCl, 5 mM KCl, 1 mM CaCl2,1m M
MgCl2, 50 mM HEPES, pH 7.4) at 37uC. After the assay buffer
was removed, 50 ml of fresh assay buffer with 5 ml of canagliflozin
(0.3–300 nM) was added, followed by 10 minutes of incubation.
Then, 5 ml of 6 mM alpha-methyl-D-glucopyranoside (AMG, a
selective SGLT1/2 substrate)/
14C-AMG (0.07 mCi) was added to
the cells and incubated at 37uC for 2 hours. Next, the cells were
washed 3 times with 0.15 ml ice-cold phosphate-buffered saline
(PBS). After the final wash was aspirated, 50 ml of microscint 20
(Packard, Meriden, Connecticut, USA) was added. The plate was
counted by TopCount (Packard, Meriden, Connecticut, USA).
The 2-deoxy-glucose (2-DG) Uptake in L6 Myoblast
Cells. Cells from the rat skeletal muscle cell line, L6, was used
to test the effect of canagliflozin on glucose transporter 1 (GLUT1)
activity. Cells were maintained in Dulbecco’s modified Eagle’s
medium containing 5.6 mM glucose supplemented with 10% fetal
bovine serum, were seeded in 24-well plates at a density of
3.0610
5 cells/well and cultured for 24 hours in an atmosphere of
5% CO2 at 37uC. Cells were rinsed twice with Kreb’s ringer
phosphate HEPES buffer (pH 7.4, 150 mM NaCl, 5 mM KCl,
1.25 mM MgSO4, 1.25 mM CaCl2, 2.9 mM Na2HPO4,1 0m M
HEPES) and were pre-incubated with the solutions of canagliflozin
(250 ml, 10 uM) for 5 minutes at room temperature. The transport
reaction was initiated by adding 50 ml of 4.5 mM 2-DG (a
substrate for GLUTs)/
3H-2-DG (0.625 mCi) followed by
incubation for 15 minutes at room temperature. The 2-DG
uptake was halted by aspiration of the incubation mixture. Cells
were immediately washed 3 times with ice-cold PBS. Samples were
extracted with 0.3 N NaOH, and radioactivity was determined by
liquid scintillation (Packard, Boston, Massachusetts, USA).
Two-electrode Voltage Clamp Recording of Oocytes
Expressing Human SGLT3. The functional effects of
canagliflozin on human SGLT3 were studied by 2-electrode
voltage clamp electrophysiology using OpusXpress 6000A (MDS
Analytical Technologies, Ontario, Canada) [16]. Oocytes were
obtained from Nasco (Fort Atkinson, Wisconsin, USA). Stage V–
VI oocytes were injected with 50 nl of either human SGLT3
mRNA (at 1 ng/nl) or distilled water (control) and incubated at
18uC in a calcium-free solution (92 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 5 mM HEPES, 0.05 mg/ml gentamicin at pH 7.5) for 4–
6 days before recording. The extracellular recording solution
contained 92 mM NaCl, 2 mM KCl, 1.8 mM CaCl2,1 m M
MgCl2, and 5 mM HEPES at pH 7.5. Injected oocytes were
impaled with 2 microelectrodes filled with 3 M KCl (resistance of
,0.5–3 MV) and voltage clamped to 2120 mV, at which
continuous recordings were made (filtered at 5 kHz and sampled
at 625 Hz). To establish the baseline in the absence of agonist,
oocytes were first perfused for 85 seconds with a control buffer
(92 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2,5m M
HEPES at pH 7.5). Next, 50 mM 1-deoxynojirimycin (DNJ) was
applied for 160 seconds, followed by co-application of imino
sugars 1-deoxynojirimycin (DNJ, 50 mM) with either canagliflozin
(10 mM) or dimethyl sulfoxide (DMSO) (0.1%) for 160 seconds.
Finally, phlorizin (3 mM) was applied in the presence of 50 mM
DNJ for 160 seconds. All experiments were performed at 22uC.
Currents in the presence of 50 mM DNJ were subtracted from leak
currents (currents in control buffer alone) to obtain DNJ-induced
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Inhibition=1006(IDNJ2Icmpd)/IDNJ, where Icmpd is the DNJ-
induced and leak-subtracted current in the presence of a
compound or DMSO. Due to lack of effect at the highest dose
tested, a dose-response relationship was not examined.
In Vivo Studies with Animal Models
Animals and Canagliflozin Administration. Four rodent
models were used in these experiments: (1) male C57BL/6J mice
fed with a high-fat diet (D-12492 with 60 kcal% fat, Research
Diets, Inc, New Jersey, USA) (diet-induced obese, insulin
resistantmice [DIO]); (2) male C57BL/ksj-db/db hyperglycemic
mice; (3) male Zucker fatty (ZF) obese, insulin resistant rats; and (4)
male ZDF obese, hyperglycemic rats. All animals were housed
according to standard procedures following a protocol approved
by the IACUC in Drug Discovery at Johnson & Johnson
Pharmaceutical Research & Development, LLC. Canagliflozin
was formulated in 0.5% hydroxypropyl methylcellulose and
administrated via oral gavage at 10 ml/kg.
Renal Glucose Handling. Two separate graded glucose
infusion (GGI) studies were performed to characterize renal
glucose handling in both untreated and treated ZDF rats. In both
experiments, rats were anesthetized with thiobutabarbital
(100 mg/kg); a catheter was inserted into the jugular vein for
glucose infusion; another catheter was introduced into the bladder
to collect urine; and a graded GGI was performed (infusion rate
increased from 1.5 ml/kg/h to 6.0 ml/kg/h of 10% glucose over
90 min) to increase BG levels. In the first study, the GGI increased
BG from overnight-fasted values of approximately 200 mg/dl to
approximately 475 mg/dl. In the second experiment, insulin was
infused (3 U/ml, 0.7 ml/kg/h) for 60 minutes to lower BG levels
to approximately 25 mg/dl, and then the GGI was performed to
increase BG to approximately 300 mg/dl over 90 minutes. Blood
and urine samples were collected for each 5-min interval to
measure glucose and creatinine levels. The RTG was determined
as described below.
Determining RTG. The relationship between UGE and BG
is commonly described as a threshold relationship in which there is
little UGE when BG,RTG and UGE increases with filtered
glucose load when BG.RTG, where the filtered glucose load is
equal to the BG concentration multiplied by the glomerular
filtration rate (GFR). The idealized threshold relationship in which
UGE is 0 whenever BG is below RTG, and then increases with the
filtered glucose load when BG.RTG, can be written
mathematically as [17,18]:
rate of UGE(mg=min)~
0 when BGƒRTG
GFR(dl=min)| BG(mg=dl)   RTG(mg=dl)
  
when BGwRTG
(
ð1Þ
Values of RTG were determined using nonlinear regression (nlinfit
in Matlab version 7.10) with Equation 1 and the measured BG and
UGE values.
Reduction of Hyperglycemia in Diabetic Rodent
Models. To examine the effect of canagliflozin on
hyperglycemia, single doses of canagliflozin (0.1, 1, and 10 mg/
kg) were administered to overnight-fasted db/db mice. BG levels
were monitored at 0, 0.5, 1, 3, 6, and 24 hours after dosing.
Canagliflozin was also administered to ZDF rats at varying doses
(3–30 mg/kg) for 4 weeks to evaluate its effect on BG control and
pancreatic beta-cell function. BG levels were monitored weekly,
and HbA1c, plasma glucose, and insulin levels were determined at
the end of the 4-week treatment. An oral glucose tolerance test
(OGTT) (2 mg/kg of body weight, given by gavage) was
conducted in ZDF rats after 4 weeks of treatment. Blood was
sampled at 0, 30, 60, and 120 minutes after glucose challenge from
the tail vein for measurement of BG levels using a glucometer
(One Touch Ultra, LifeScan, Milpitas, California, USA) and
plasma insulin using ELISA method (ALPCO, Salem, New
Hampshire, USA).
Body Weight Control Studies in Obese Mice and
Rats. The effects of canagliflozin on body weight gain were
evaluated in DIO mice and ZF rats. DIO mice received a 4-week
treatment of canagliflozin at 30 mg/kg. Body weight, food intake,
and BG levels were monitored weekly. UGE and indirect
calorimetry were conducted in the fourth week of treatment
during the compound treatment. In another study, ZF rats were
treated with canagliflozin at 3 mg/kg for 3 weeks. Body weight,
food intake, and BG were measured weekly during the 19-day
treatment period. UGE, body fat, and indirect calorimetric studies
were conducted at the end of this study.
Data Analysis. Statistical analysis was performed using the
program Prism (Graphpad, Monrovia, California, USA).
Differences between groups were evaluated using 1-way analysis
of covariance with Dunnett’s multiple comparison test or student’s
t-test (unpaired), as appropriate. Probabilities less than 5%
(P,0.05) were considered to be statistically significant. Fifty-
percent inhibitory concentration (IC50) and 95% confidence
interval (CI) were determined by nonlinear least-squares analysis
using a 4-parameter logistic model. All data are presented as mean
6 standard error.
Results
Effect of Canagliflozin on AMG Uptake in CHO Cells
Expressing SGLTs and 2-DG Uptake in L6 Myoblast Cells
In a concentration-dependent fashion, canagliflozin inhibited
Na
+-dependent
14C-AMG uptake in CHO-hSGLT2 cells, with an
IC50 of 4.461.2 nM. Similar IC50 values were obtained in CHO-
rSGLT2 and CHO-mSGLT2 cells (IC50=3.7 and 2.0 nM for rat
and mouse SGLT2, respectively). Canagliflozin inhibited
14C-
AMG uptake in CHO-hSGLT1 and mSGLT1 cells with IC50 of
6846159 nM and .1,000 nM, respectively. The IC50 values for
hSGLT1 and hSGLT2 are similar to previously reported values
for canagliflozin [19]. Figure 1 represents results from a typical
experiment. At 10 mM, canagliflozin inhibited the facilitative (non-
Na
+-linked) GLUT-mediated 3H-2-DG uptake in L6 myoblasts by
less than 50% (Table 1).
Effects of Canagliflozin on hSGLT3 Exogenously
Expressed in Oocytes
It has been reported recently that SGLT3 functions as a glucose
sensor [20]. To explore the effects of canagliflozin on the function
of this protein, human SGLT3 was expressed in oocytes. In sham
(water)-injected oocytes, imino sugars 1-deoxynojirimycin (DNJ,
50 mM) did not induce currents. By contrast, ooctyes injected with
human SGLT3 mRNA expressed significant DNJ-sensitive
currents (21.661.1 nA [n=14] for sham-injected versus
43.462.9 nA [n=60] for SGLT3-injected oocytes; P,0.05). In
sham-injected oocytes, canagliflozin (10 mM) or phlorizin (3 mM)
alone in the presence of 50 mM DNJ did not affect currents. In
SGLT3-injected oocytes, DMSO and canagliflozin 10 mM
inhibited DNJ-induced currents by 15.663.1% (n=5) and
23.464.3% (n=9), respectively. The difference between DMSO
and canagliflozin treatments was not statistically significant. In
contrast, phlorizin (3 mM) caused significant (P,0.05) inhibition
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n=14; Table 1).
Effect of Canagliflozin on the Relationship between BG
and UGE
Two separate GGI studies were performed to characterize the
relationship between BG and UGE in untreated and treated ZDF
rats. In the first study, untreated ZDF rats given a GGI to raise BG
from approximately 200 mg/dl to approximately 475 mg/dl did
not experience appreciable UGE until BG levels were .400 mg/
dl and RTG=415612 mg/dl. Canagliflozin treatment (1 mg/kg)
notably lowered RTG in ZDF rats to 94610 mg/dl (Figure 2). In
the second study, an insulin infusion was given to lower BG to
approximately 25 mg/dl, and then the GGI was given to slowly
raise BG to approximately 300 mg/dl. In ZDF rats treated with
canagliflozin (1 mg/kg), the relationship between BG and UGE
remained well-described by a threshold relationship with negligi-
ble UGE occurring when BG,90 mg/dl and UGE increased in
proportion to BG at higher BG levels, whereas virtually no UGE
was observed in vehicle-treated animals in this study (Figure 2).
Effect of Canagliflozin on Glycemic Control in db/db Mice
and ZDF Rats
In db/db mice, single doses of canagliflozin dose-dependently
reduced non-fasting BG concentrations. The onset of the BG-
lowering effect after a single dose was rapid, and BG levels in
canagliflozin-treated mice (at 1 and 10 mg/kg doses) were
significantly different from those of vehicle-treated mice at 1 hour
after treatment (22% and 36% reduction of BG levels compared
with that in vehicle-treated mice [P,0.5], respectively). This
antihyperglycemic effect reached its peak at 6 hours (BG levels at
20869.6 or 11869.0 mg/dl in db/db mice treated with 1 or
10 mg/kg, respectively, compared with BG level of 47963.9 mg/
dl in vehicle-treated mice). To evaluate the chronic effect of
Figure 1. Inhibitory effects of canagliflozin on human SGLT1 and human SGLT2. The inhibitory effect of canagliflozin on
14C-AMG uptake
in CHOK-hSGLT1 and CHOK-hSGLT2 has been measured in 5 experiments. A typical inhibitory effect on CHOK-hSGLT1 (Panel A) and CHOK-hSGLT2
(Panel B) from a single experiment is presented here.
doi:10.1371/journal.pone.0030555.g001
Table 1. Effects of canagliflozin on SGLT1-, SGLT2-, and facilitative glucose transporter-mediated glucose transport, and on SGLT3-
induced currents.
Cells line SGLT tested Substrate for transporter IC50,n M
CHOK cells Human SGLT1
14C-AMG 6846159
Human SGLT2
14C-AMG 4.461.2
Rat SGLT1
14C-AMG 571
Rat SGLT2
14C-AMG 3.7
Mouse SGLT1
14C-AMG .1000
Mouse SGLT2
14C-AMG 2.0
Rat L6 myoblast cells
3H-2-DG .10,000
Oocytes Human SGLT3 DNJ-induced currents No inhibitory effect
CHOK cells over-expressed with human, rat, or mouse SGLT1 or SGLT2 and rat L6 myoblast cells were used. AMG or 2-DG uptake was determined and IC50 values were
calculated as described in Methods section. Data of human SGLT1 and SGLT2 were presented the summary of 5 studies. Other data presented the mean value of2
experiments. Oocytes expressed with human SGLT3 were used to determine canagliflozin effect on DNJ-induced current.
2-DG, 2-deoxy-D-glucose; AMG, alpha-methylglucoside; CHOK, Chinese hamster ovary-K; IC50, concentration required to inhibit 50% of activity; SGLT, sodium glucose co-
transporter; DNJ, imino sugars 1-deoxynojirimycin.
doi:10.1371/journal.pone.0030555.t001
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compound at doses of 3, 10, or 30 mg/kg for 4 weeks. The non-
fasting BG and HbA1c levels decreased in all canagliflozin-treated
rats compared with the vehicle-treated group (Table 2). Canagli-
flozin treatment also reduced BG levels in ZDF rats following an
OGTT (Table 2) after 4 weeks of treatment. Canagliflozin
treatment improved beta-cell function as demonstrated by a 4-
to-6-fold increase, relative to vehicle-treated animals, in the
insulin/glucose ratio following an OGTT (Table 2).
Effect of Canagliflozin on Body Weight Gain in DIO Mice
and ZF Rats
In DIO mice, canagliflozin 30 mg/kg treatment for 4 weeks
reduced BG levels, respiratory exchange ratio, and body weight
gain (Table 3). In ZF rats treated with canagliflozin 3 mg/kg for 3
weeks, UGE was increased with no significant change in total food
intake compared with that in vehicle-treated rats, leading to a
decrease in body weight. Relative to vehicle-treated ZF rats,
canagliflozin-treated ZF rats had a reduction in respiratory
exchange ratio. The weight of epididymal fat pads and liver
tissues in compound-treated groups tended to be reduced. Feeding
efficiency, defined as the body weight gain divided by the food
intake, decreased in canagliflozin-treated ZF rats (Table 3).
Discussion
Based on in vitro assessments, canagliflozin is a potent and
selective SGLT2 inhibitor. By inhibiting SGLT2, canagliflozin
lowers the renal glucose resorptive capacity and increases UGE.
The GGI studies performed demonstrate that the relationship
Figure 2. BG and UGE in untreated and CANA-treated ZDF rats during two GGI studies. In the first study (GGI only), a GGI was given to
untreated ZDF rats (n=8) to raise BG from 212624 mg/dl to ,475 mg/dl over 90 minutes. In the second study (Insulin+GGI), ZDF rats (n=6/group)
were treated with either vehicle or canagliflozin (1 mg/kg), then given insulin to lower BG to 2561 mg/dl, and finally given the GGI to slowly raise BG.
BG and UGE were measured every 5 minutes. Results shown are mean 6 S.E. GGI, graded glucose infusion; BG, blood glucose; UGE, urinary glucose
excretion; ZDF, Zucker diabetic fatty rats; GG1, graded glucose infusion.
doi:10.1371/journal.pone.0030555.g002
Table 2. Effects of a 4-week treatment of canagliflozin on blood glucose and insulin levels in ZDF rats.
Vehicle 3 mg/kg 10 mg/kg 30 mg/kg
Fed plasma glucose (mg/dl) 598.2618.0 248.0613.5
a 182.067.1
a 199.9614.7
a
HbA1c (%) 11.560.3 7.160.3
a 5.660.3
a 5.560.3
a
Insulin (ng/ml) 5.260.4 7.960.1
a 7.960.1
a 7.860.1
a
OGTT
Blood glucose (AUC0–120 min, mg/dlNmin) 70,70461289 27,88361806
a 23,98961881
a 16,5496822
a
Plasma insulin (AUC0–120 min, ng/mlNmin) 221613 342627
a 403633
a 288634
Ratio of insulin AUC/glucose AUC (ng/mlNmin)/mg/dlNmin) 0.00360.000 0.01360.002
a 0.01760.002
a 0.01860.002
a
ZDF rats were treated with different doses of canagliflozin or vehicle for 4 weeks. Fed plasma glucose levels, HbA1c, and plasma insulin were determined at the end of
this study. In addition, an OGTT was conducted. Blood glucose, plasma insulin, and urine glucose excretion were measured during OGTT. Data are presented as mean 6
SEM (n=8).
AUC, area under the curve; HbA1c, glycated hemoglobin; OGTT, oral glucose tolerance test; ZDF, Zucker diabetic fatty.
ap,0.05 compared with vehicle-treated group.
doi:10.1371/journal.pone.0030555.t002
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well described by a threshold relationship such that UGE in
canagliflozin-treated animals remained near zero when BG levels
were below RTG, and increased as BG increased when BG levels
were above RTG. Canagliflozin treatment (1 mg/kg) lowered
RTG in ZDF rats from 415612 mg/dl to 94610 mg/dl. RTG
values in the untreated ZDF rats were considerably higher than
values of 180–200 mg/dl commonly reported in humans [21,22].
The higher RTG values observed in the ZDF rats compared with
humans may be due in part to interspecies differences but may also
be due to increased expression of renal glucose transporters that
has been reported in diabetic rodents [23–25] and humans [26].
Consistent with the elevated renal glucose transporter expression,
increased renal glucose re-absorptive capacity has been reported in
humans with type 1 [27] and type 2 [28] diabetes.
In preclinical models of insulin resistance and diabetes, SGLT2
inhibitors improve beta-cell function and preserve islet morphol-
ogy [29,30]. As assessed using insulin/glucose ratio during the
OGTT, canagliflozin improved beta-cell function in ZDF rats.
SGLT2 inhibition may indirectly improve beta-cell function by
reducing the toxic effects of hyperglycemia on the beta cell (i.e.,
reducing glucotoxicity) [31]. By reducing hyperglycemia via a
non–insulin-dependent mechanism, SGLT2 inhibition decreases
the demand on beta cells to secrete insulin. Increased insulin
secretory demand results in endoplasmic reticulum stress, which in
turn can lead to increases in beta-cell apoptosis [32]. A reduction
in insulin secretory demand and, consequently, endoplasmic
reticulum stress, could reduce beta-cell apoptosis, a condition
increased in patients with T2DM [33]. Thus, by reducing demand
on beta cells to secrete insulin as well as reducing glucotoxicity,
SGLT2 inhibitors theoretically could reduce the rate of progres-
sion of T2DM [34–37].
In DIO mice and ZF insulin-resistant rats, caloric loss due to
canagliflozin-induced increases in UGE was associated with
reductions in body weight gain, epididymal fat mass, and hepatic
weight. Additionally, a reduction in the respiratory exchange ratio,
suggestive of increased fatty acid metabolism and/or reduced de
novo lipogenesis, was observed in canagliflozin-treated animals.
No compensatory increase in food consumption was detected in
animals treated with canagliflozin. Although not directly assessed
in this study, SGLT2 inhibitor-induced weight loss could indirectly
improve insulin sensitivity. The reduction in liver weight and in
respiratory quotient (RQ) observed in our studies are consistent
with observations in gene-targeted mice lacking SGLT2 that
indicate in mice lacking SGLT2 and fed with high-fat diet an
increase in lipid oxidation, a reduction in hepatic glycogen
content, and a decrease in RQ [38] relative to wild-type mice. In
preclinical models of insulin resistance, improvements in insulin
sensitivity, especially in hepatic insulin sensitivity, have been noted
in animals treated with SGLT2 inhibitors [39].
A number of SGLT2 inhibitors, including canagliflozin, are in
late-stage clinical development [12–14]. Many of the preclinical
pharmacology findings with canagliflozin have been recapitulated
in clinical trials with canagliflozin and other selective SGLT2
inhibitors. For instance, in patients with T2DM, treatment with
SGLT2 inhibitors has led to improved glycemic control, reductions
in body weight, and improvements in beta-cell function [40–43].
In summary, our current studies demonstrated that canagli-
flozin is a potent and selective SGLT2 inhibitor that lowers RTG,
increases UGE, improves glycemic control, improves beta-cell
function, reduces body weight, increases fatty acid oxidation, and
reduces de novo lipogenesisin rodent models of insulin resistance
and T2DM. These preclinical data suggest that canagliflozin may
provide benefits beyond improving glycemic control in the
treatment of T2DM and support the clinical development of
canagliflozin to more fully characterize the benefit-risk profile of
this agent in treating T2DM.
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Table 3. Effects of canagliflozin on body weight, glycemia, UGE, and respiratory exchange ratio in DIO mice and ZF rats.
a
Treatment ZF rat DIO mouse
Vehicle 3 mg/kg Vehicle 30 mg/kg
Body weight (g) 437.9611.5 408.167.7
b 53.260.6 49.661.0
b
Total food intake (g) 645.3621.2 647.9618.9 ND ND
Feeding efficiency index (body weight gain/food intake) 0.3060.01 0.2560.01
{ ND ND
Fed BG (mg/dl) 149.6622.9 118.964.3
b 199616 105613
b
UGE (mg/4 h) 1.861.1 29.1063.5
b 2.460.6 26.165.2
b
RER 1.1060.01 1.0660.01
b 0.7960.01 0.7760.01
b
Oxygen consumption (VO2, ml/kgNh) 1560628 1582633 2364629 24196109
Epididymal fat weight (g) 10.860.3 9.560.3
b ND ND
Liver weight (g) 28.560.8 25.061.4
b ND ND
DIO mice were treated with either vehicle or canagliflozin 30 mg/kg for 4 weeks. Body weight was monitored twice per week. BG, UGE, and energy expenditure were
measured at the end of this study.
BG, blood glucose; DIO, diet-induced obesity; ND, not detected; RER, respiratory exchange ratio; UGE, urinary glucose excretion; VO2, oxygen consumption; ZF, Zucker
fatty.
aZF rats were treated with either vehicle or canagliflozin 3 mg/kg for 3 weeks. Body weight and food intake were monitored twice per week. BG, UGE, and energy
expenditure were measured at the end of this study. In addition, the weight of epididymal fat pad and liver tissue were determined during necropsy. Data are
presented as mean 6 SEM (n=8).
bp,0.05 compared with vehicle-treated group.
doi:10.1371/journal.pone.0030555.t003
Canagliflozin on Renal Threshold
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e30555Author Contributions
Conceived and designed the experiments: YL KA KU YM CK TM FD
YL JX BC JC DP. Performed the experiments: YL KA KU YM CK TM
FD YL JX BC JC DP. Analyzed the data: YL KA KU YM CK TM FD YL
JX BC JC DP KW KD. Contributed reagents/materials/analysis tools: YL
KA KU YM CK TM FD YL JX BC JC DP. Wrote the paper: KW KD.
References
1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of
diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 27:
1047–1053.
2. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB (2008) Is glycemic control
improving in U.S. adults? Diabetes Care 31: 81–86.
3. Wright EM, Hirayama BA, Loo DF (2007) Active sugar transport in health and
disease. J Intern Med 261: 32–43.
4. Wright EM, Turk E (2004) The sodium/glucose cotransport family SLC5.
Pflu ¨gers Arch - Eur J Physiol 447: 510–518.
5. Kloeckener-Gruissem B, Vandekerckhove K, Nu ¨rnberg G, Neidhardt J, Zeitz C,
et al. (2008) Mutation of solute carrier SLC16A12 associates with a syndrome
combining juvenile cataract with microcornea and renal glucosuria. Am J Hum
Genet 82: 772–779.
6. Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a
mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5: 133–141.
7. Wright EM (1998) Genetic disorders of membrane transport: I. Glucose
galactose malabsorption. Am J Physiol Gastrointest Liver Physiol 275:
G879–G882.
8. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, et al. (2010) SGLT2
mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol
22: 104–112.
9. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J (2005) Phlorizin: a review.
Diabetes Metab Res Rev 21: 31–38.
10. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA (1987) Effect of chronic
hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.
J Clin Invest 80: 1037–1044.
11. Mather A, Pollock C (2010) Renal glucose transporters: novel targets for
hyperglycemia management. Nat Rev Nephrol 6: 307–311.
12. Nair S, Wilding J (2010) Sodium glucose cotransporter 2 inhibitors as a new
treatment for diabetes mellitus. J Clin Endocrinol Metab 95: 34–42.
13. Bakris GL, Fonseca VA, Sharma K, Wright EM (2009) Renal sodium-glucose
transport: role in diabetes mellitus and potential clinical implications. Kidney Int
75: 1272–1277.
14. Chao EC, Henry RR (2010) SGLT2 inhibition – a novel strategy for diabetes
treatment. Nat Rev Drug Discov 9: 551–559.
15. Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, et al. (2010)
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-
dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes
mellitus. J Med Chem 53: 6355–6360.
16. Voss AA, Dı ´ez-Sampedro A, Hirayama BA, Loo DF, Wright EM (2007) Imino
sugars are potent agonists of the human glucose sensor SGLT3. Mol Pharmacol
71: 628–634.
17. Magni L, Raimondo DM, Bossi L, Man CD, De Nicolao G, et al. (2007) Model
predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 6:
804–12.
18. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, et al. (2011) Canagliflozin, a
novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces
calculated renal threshold for glucose excretion and increases urinary glucose
excretion in healthy subjects. Diabetes Obes Metab 13: 669–672.
19. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, et al. (2011)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2)
inhibitor: characterisation and comparison with other SGLT-2 inhibitors
[published online ahead of print October 12, 2011] Diabetes Obes Metab doi:
10.1111/j.1463-1326.2011.01517.x.
20. Diez-Sampedro A, Hirayama BA, Osswald C, Gorboulev V, Baumgarten K,
et al. (2003) A glucose sensor hiding in a family of transporters. Proc Natl Acad
Sci USA 100: 11753–11758.
21. Nair S, Wilding J (2010) Sodium glucose cotransporter 2 inhibitors as a new
treatment for diabetes mellitus. J Clin Endocrinol Metab 95: 34–42.
22. Rave K, Nosek L, Posner J, Heise T, Roggen K, et al. (2006) Renal glucose
excretion as a function of blood glucose concentration in subjects with type 2
diabetes—results of a hyperglycaemic glucose clamp study. Nephrol Dial
Transplant 21: 2166–2171.
23. Vestri S, Okamoto MM, Freitas HS, dos Santos RA, Nunes MT, et al. (2001)
Changes in sodium or glucose filtration rate modulate expression of glucose
transporters in renal proximal tubular cells of rat. J Membr Biol 182: 105–112.
24. Freitas HS, Anhe ˆ GF, Melo KFS, Okamoto MM, Oliveira-SouzaM, et al. (2008)
Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of
diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear
factor-1alpha expression and activity. Endocrinology 149: 717–724.
25. Kamran M, Peterson R, Dominguez J (1997) Overexpression of GLUT2 gene in
renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 8: 943–948.
26. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, et al. (2005)
Glucose transporters in human renal proximal tubular cells isolated from the
urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427–3434.
27. Mogensen CE (1971) Maximum tubular reabsorption capacity for glucose and
renal hemodynamcis during rapid hypertonic glucose infusion in normal and
diabetic subjects. Scand J Clin Lab Invest 28: 101–109.
28. Farber SJ, Berger EY, Earle DP (1951) Effect of diabetes and insulin on the
maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30:
125–129.
29. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, et al. (2001) Improved
diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the
Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132: 578–586.
30. Nunoi K, Yasuda K, Adachi T, Okamoto Y, Shihara N, et al. (2002) Beneficial
effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on
metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin
Exp Pharmacol Physiol 29: 386–390.
31. Del Prato S (2009) Role of glucotoxicity and lipotoxicity in the pathophysiology
of type 2 diabetes mellitus and emerging treatment strategies. Diabetic Med 26:
1185–1192.
32. Eizirik DL, Cardozo AK, Cnop M (2008) The role for endoplasmic reticulum
stress in diabetes mellitus. Endocr Rev 29: 42–61.
33. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, et al. (2003) Beta-cell
deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Diabetes 52: 102–110.
34. Ueta K, Ishihara T, Matsumoto Y, Oku A, Nawano M, et al. (2005) Long-term
treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained
improvement in hyperglycemia and prevents diabetic neuropathy in Goto-
Kakizaki rats. Life Sci 76: 2655–2668.
35. Kahn SE (2001) Clinical review 135: the importance of beta-cell failure in the
development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:
4047–4058.
36. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, et al. (2009)
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in
streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 609:
148–154.
37. Oku A, Ueta K, Nawano M, Arakawa K, Kano-Ishihara T, et al. (2000)
Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in
neonatally streptozotocin-treated rats. Eur J Pharmacol 391: 183–192.
38. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, et al. (2011)
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-
cell function. Diabetes 60: 890–898.
39. Han S, Hagan DL, Taylor JR, Xin L, Meng W, et al. (2008) Dapagliflozin, a
selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic
rats. Diabetes 57: 1723–1729.
40. Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W (2010)
Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2),
improves glycemic control and lowers body weight in subjects with type 2
diabetes on metformin. Diabetes 59: A78.
41. Wilding JP, Norwood P, T’joen C, Bastien A, List JF, et al (2009) A study of
dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus
insulin sensitizers: applicability of a novel insulin-independent treatment.
Diabetes Care 32: 1656–1662.
42. List JF, Woo V, Morales E, Tang W, Fiedorek FT (2009) Sodium–glucose
cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:
650–657.
43. Bailey CJ, Gross JL, Pieters A, Bastien A, List J (2010) Effect of dapagliflozin in
patients with type 2 diabetes who have inadequate glycaemic control with
metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:
2223–2233.
Canagliflozin on Renal Threshold
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e30555